The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ajp.120.9.905

Our conclusion is that methotrimeprazine is clinically useful in controlling marked disturbances of behavior in psychotic patients when administered muscularly. It is more hypnotic than chlorpromazine, and it is possibly less anti-psy-chotic. But it is free of the untoward effects to the tissues as no signs or symptoms of tissue damage were observed. It is very helpful in controlling the acutely disturbed patient, including the aged, if the few basic precautions are observed for parenteral use.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.